Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Capital Employed (2016 - 2025)

Altimmune (ALT) has disclosed Return on Capital Employed for 15 consecutive years, with 0.47% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 26.0% to 0.47% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.47%, a 26.0% increase, with the full-year FY2024 number at 0.63%, down 14.0% from a year prior.
  • Return on Capital Employed was 0.47% for Q3 2025 at Altimmune, up from 0.57% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.25% in Q1 2021 to a low of 0.78% in Q4 2024.
  • A 5-year average of 0.52% and a median of 0.5% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: grew 30bps in 2021, then decreased -27bps in 2022.
  • Altimmune's Return on Capital Employed stood at 0.46% in 2021, then grew by 5bps to 0.44% in 2022, then dropped by -23bps to 0.54% in 2023, then crashed by -43bps to 0.78% in 2024, then skyrocketed by 39bps to 0.47% in 2025.
  • Per Business Quant, the three most recent readings for ALT's Return on Capital Employed are 0.47% (Q3 2025), 0.57% (Q2 2025), and 0.71% (Q1 2025).